Preliminary data from Stage 1 of the study indicated alvocidib in combination with cytarabine and mitoxantrone has shown encouraging activity in 18 patients with MCL-1-dependent AML, with the majority of patients achieving a complete remission (CR) or complete remission with incomplete recovery (CRi).
The study found an overall CR/CRi rate of 61% and an overall response rate (ORR) of 67%. In patients who were refractory to frontline therapy, CR/CRi rate was 75% and ORR was 88%. Patients that attained a CR/CRi experienced a median duration of response of 8.2 months and median overall survival of 10.1 months.
In addition, 44% of patients proceeded to post-study stem cell transplant, including 63% of previously refractory patients.
Tolero is a clinical-stage biopharmaceutical company researching and developing treatments for patients with oncological and hematological diseases.
Its diverse pipeline targets biological drivers of blood disorders to treat leukemias, anemia, and solid tumors, as well as targets of drug resistance and transcriptional control. Tolero, based in the United States, is a wholly owned subsidiary of Japan-based Sumitomo Dainippon Pharma Co., Ltd.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval